Marimed (MRMD) Total Non-Current Liabilities (2011 - 2025)
Marimed (MRMD) posted quarterly Total Non-Current Liabilities of $137.8 million for Q4 2025, up 6.56% year-over-year from $129.3 million in Q4 2024, and up 1.01% quarter-over-quarter from $136.5 million in Q3 2025.
Marimed (MRMD) Total Non-Current Liabilities (2011 - 2025) Analysis & Trends
Marimed (MRMD) has reported Total Non-Current Liabilities for 15 consecutive years, with $137.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 6.56% year-over-year to $137.8 million; the TTM figure through Dec 2025 stood at $137.8 million (up 6.56% YoY), while the FY2025 annual figure was $137.8 million, up 6.56% from the prior year.
- Total Non-Current Liabilities advanced to $137.8 million in Q4 2025 per MRMD's latest filing, from $136.5 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $137.8 million in Q4 2025 and bottomed at $37.5 million in Q1 2021.
- Historically, Total Non-Current Liabilities has averaged $89.3 million across 5 years, with a median of $89.2 million in 2023.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities slumped 36.32% — and 2023, when it jumped 87.69%.
- Marimed's Total Non-Current Liabilities stood at $49.1 million in 2021, then gained by 16.27% to $57.1 million in 2022, then surged by 87.69% to $107.1 million in 2023, then rose by 20.76% to $129.3 million in 2024, then gained by 6.56% to $137.8 million in 2025.
- Business Quant data shows MRMD's Total Non-Current Liabilities at $137.8 million in Q4 2025, $136.5 million in Q3 2025, and $131.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 334.00 Mn |
| 10 | Marimed | 27.77 Mn | 19.33 Mn | 16.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 137.83 Mn |
| Sep 30, 2025 | 136.45 Mn |
| Jun 30, 2025 | 131.10 Mn |
| Mar 31, 2025 | 133.96 Mn |
| Dec 31, 2024 | 129.34 Mn |
| Sep 30, 2024 | 125.74 Mn |
| Jun 30, 2024 | 120.83 Mn |
| Mar 31, 2024 | 113.41 Mn |
| Dec 31, 2023 | 107.11 Mn |
| Sep 30, 2023 | 91.86 Mn |
| Jun 30, 2023 | 86.46 Mn |
| Mar 31, 2023 | 81.30 Mn |
| Dec 31, 2022 | 57.07 Mn |
| Sep 30, 2022 | 55.00 Mn |
| Jun 30, 2022 | 50.60 Mn |
| Mar 31, 2022 | 55.57 Mn |
| Dec 31, 2021 | 49.08 Mn |
| Sep 30, 2021 | 45.11 Mn |
| Jun 30, 2021 | 40.28 Mn |
| Mar 31, 2021 | 37.46 Mn |